VALNValneva SE
$5.30-47% 1Y
$5.30
$4.7852 weeks$11.99
Is the business good?
Good
1 good, 3 without dataMargins widening. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Margin direction, 3 years+10.1 ptsderived
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is VALN?
Valneva SE keeps −47% of every revenue dollar as operating profit, against −82% for the median Biotechnology name.
−47%
Operating margin · Biotechnology median −82% · 12 months to Q4 2025
- R&D as % of revenue
- 49%
R&D as % of revenue
- Gross margin
- 39%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −50% |
| FY2021 | −18% |
| FY2022 | −31% |
| FY2023 | −53% |
| FY2024 | 7.9% |
| FY2025 | −47% |
Details›
- Gross margin12 months to Q4 2025
- 39%
- Operating margin12 months to Q4 2025
- −47%
- Net margin12 months to Q4 2025
- −66%
- Free cash flow margin
- −33%
- R&D as % of revenue
- 49%
- Revenue, trailing twelve months
- $175M
- Free cash flow, trailing twelve months
- −$57M
- Net income, trailing twelve months
- −$115M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.